Almaden Genomics Adds Pre-Built Workflows to g.nome, Facilitating and Speeding Single-Cell RNA-seq Analysis

Almaden Genomics has added pre-built workflows for single-cell RNA-seq analysis to its g.nome™ platform, enabling understanding of cellular diversity and disease mechanisms on a much more granular level. By unlocking single-cell sequencing data through efficient and powerful analysis, g.nome can now help researchers better understand cellular heterogeneity and gene expression.

AVIA’s National Generative AI Collaborative Grows to Nearly Thirty Major Health Systems

BioIVT to Host a Webinar on Optimizing Liquid Biopsy Research

This webinar will discuss the importance of using standardized collection protocols and a diverse donor base to validate biomarkers and ensure their clinical utility.

Scitara and IDT present a composable IT architecture platform at Lab of The Future Europe 2023

Emendo Biotherapeutics Leaders Share Expert Insights on Cutting-Edge Gene Editing Advancements at October Industry Conferences

Executive Team Charts Path to Future Approval as the World Awaits a Historic Breakthrough in Precision Medicine

Takara Bio enters into a license agreement of RetroNectin® with Fondazione Telethon ETS

Takara Bio Inc. has announced that it has entered into a License Agreement with non-profit/charity organization, Telethon.

Integrated DNA Technologies Reveals Launch of xGen™ Products for Ultima Genomics®

IDT is the first company to offer stocked products for Ultima Genomics platforms. Products include xGen™ NGS adapters, primers and universal blockers.

New hot start isothermal mixes boost sensitivity, specificity, and speed of DNA target detection

PCR Biosystems, a leading PCR reagent developer, has launched a new range of Bst polymerase reagents that offer greater sensitivity, speed, and specificity in all isothermal amplification applications.

Phenomix Sciences Co-Founders Awarded First Patent for Using Precision Medicine and Phenotyping to Treat Obesity

Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data-driven precision medicine to obesity treatment, announced today the United States Patent and Trademark Office (USPTO) has issued the first patent related to its obesity phenotyping technology.

Creative Proteomics Introduces Mature Solutions for Membrane Protein Identification

Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

Laverock Therapeutics, established in 2021 to commercialise the gene editing induced gene silencing (GEiGS®) platform for all human therapeutic applications, is pleased to announce that it has expanded its seed funding round to £13.5M.

Creative Proteomics Launches State-of-the-Art Peptide Sequencing Service to Advance Proteomics Research

Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treatment

Creative Proteomics Leads the Way with Cutting-Edge RNA Pull Down Service

HERMES PHARMA announces €25 million investment to bolster capacity

HERMES PHARMA, the leading expert in user-friendly oral dosage forms, has announced it will invest €25 million to further bolster its manufacturing capabilities.

Announcing Kivo GO: An intuitive DMS to accelerate speed-to-market for life sciences

Kivo today introduced Kivo GO, a unified platform for emerging life sciences teams who need to work together efficiently across all functions while maintaining compliance and security.

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Cytel continues expansion of market access and medical communication capabilities with the acquisition of co.faktor

Cytel Inc. has acquired the Berlin-based company co.faktor GmbH.

Discovery Park selects 13 start-ups to join Discovery Spark life science programme

Thirteen life science start-ups have been accepted onto Discovery Park’s new business support programme and competition, Discovery Spark. The eight-week Discovery Spark programme will equip the early-stage companies with the necessary skills to catalyse their business growth plans and gives them the chance to win a business support package worth over £100,000.

Sygnature Discovery successfully identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation